

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 9/16, 9/48, 9/50, 9/72, 48/00</b>		A1	(11) International Publication Number: <b>WO 97/36578</b> (43) International Publication Date: <b>9 October 1997 (09.10.97)</b>
<p>(21) International Application Number: <b>PCT/GB97/00953</b></p> <p>(22) International Filing Date: <b>3 April 1997 (03.04.97)</b></p> <p>(30) Priority Data: 9607035.4 3 April 1996 (03.04.96) GB PCT/GB96/01379 7 June 1996 (07.06.96) WO</p> <p>(34) Countries for which the regional or international application was filed: <b>GB et al.</b></p>		<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>	
<p>(71) Applicant (for all designated States except US): <b>ANDARIS LIMITED [GB/GB]</b>; 1 Mere Way, Ruddington, Nottingham NG11 6JS (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): <b>SUTTON, Andrew, Derek [GB/GB]</b>; 12 Grampian Way, Gonerby Hill Foot, Grantham NG31 8FY (GB). <b>OGDEN, Jill, Elizabeth [GB/GB]</b>; Andaris Limited, 1 Mere Way, Ruddington, Nottingham NG11 6JS (GB). <b>JOHNSON, Richard, Alan [GB/GB]</b>; Andaris Limited, 1 Mere Way, Ruddington, Nottingham NG11 6JS (GB).</p> <p>(74) Agent: <b>GILL JENNINGS &amp; EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB)</b>.</p>		<p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: **SPRAY-DRIED MICROPARTICLES AS THERAPEUTIC VEHICLES FOR USE IN GENE THERAPY**

(57) Abstract

Microparticles, which are smooth and spherical, and at least 90 % of which have a volume median particle size of 1 to 10  $\mu\text{m}$ , comprise a substantially uniform mixture of an agent for gene therapy and an excipient. For example, a naked or encapsulated gene can thus be administered, using a dry powder inhaler.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SPRAY-DRIED MICROPARTICLES AS THERAPEUTIC VEHICLES FOR  
USE IN GENE THERAPY

Field of the Invention

5 This invention relates to spray-dried microparticles and their use as therapeutic vehicles. In particular, the invention relates to means for delivery of agents for gene therapy.

Background of the Invention

10 Current methods of aerosolising drugs for inhalation include nebulisation, metered dose inhalers and dry powder inhaler systems. Nebulisation of aqueous solutions and suspensions requires large volumes of drugs and involves the use of bulky and non-portable devices.

15 The most common method of administration of therapeutic agents to the lung is by the use of volatile propellant-based devices, commonly termed metered dose inhalers. A solution of propellant, commonly CFC 11, 12 or 114, is used, containing either dissolved drug or a suspension of the drug in a pressurised canister. Dosing 20 is achieved by depressing an actuator which releases a propellant aerosol of drug suspension or solution which is carried on the airways. During its passage to the lung, the propellant evaporates to yield microscopic precipitates from solution or free particles from suspension. The 25 dosing is fairly reproducible and cheap, but there is growing environmental pressure to reduce the use of CFCs. CFCs will shortly be replaced by non-ozone-depleting propellants, so-called hydrofluoroalkanes. Furthermore, the use of CFC solvents remains largely incompatible with 30 many drugs, because of their susceptibility to denaturation and low stability.

Concurrently, there is a move towards using dry powder inhalers (DPIs) containing drugs, usually admixed with a carrier, such as mannitol, lactose or glucose, which 35 facilitates the aerosolisation and dispersion of the drug particles. The energy for disaggregation is often supplied

by the breath or inspiration of air through the device by the patient.

Drugs are currently micronised, to reduce particle size. This approach is not applicable for biotechnology products. In general, biotechnology products are available in low quantity and, furthermore, are susceptible to the methods currently employed to dry and micronise drugs, prior to mixing with carrier. Further, it is particularly difficult to provide blends of drug and carrier which are sufficiently free-flowing that they flow and dose reproducibly in modern multiple dose inhalers such as the Turbohaler (Astra) and Diskhaler (Glaxo).

WO-A-9116882 describes the use of spray-drying to produce lipid/drug powders of conventional asthma drugs which purportedly showed a sustained release effect due to the presence of the lipid. The conditions given for spray-drying produce dry powders which are bimodally distributed, with peaks at 1  $\mu\text{m}$  and 7-10  $\mu\text{m}$ .

WO-A-8806441 describes the use of spray-drying in the production of stable liposome formulations. A preserving additive such as a sugar is spray-dried with the lipid material. The liposomes retain their size distribution and integrity, on reconstitution. The stabilised liposomes may contain a therapeutic agent, apparently for use after storage of the liposomes and the removal of the preserving additive.

1-5  $\mu\text{m}$  is the optimal particle size for penetration to the alveolar regions. Adsorption in the alveolar region offers the largest surface area for access to the bloodstream, and therefore it is desirable that a dry powder formulation should contain a large preponderance of particles with these dimensions. It has proved difficult to produce particles in this range reproducibly by micronisation techniques. Whilst there have been preliminary reports on the use of spray-drying to produce respirable powders, the first description of the precise process conditions leading to particles for therapeutic

use, having satisfactory narrow interquartile ranges, in the 1-5  $\mu\text{m}$  range, is in WO-A-9609814 (Andaris).

While microparticles in the 1-5  $\mu\text{m}$  range are of optimal size for alveolar penetration when aerosolised as discrete particles, they do not always possess the necessary bulk powder flow properties which are required for DPI device filling and dose dispensing. Particles of this size are highly cohesive and will generally require coarser-sized particles to impart the bulk flow properties required; larger particles flow better. For drugs that have low potency, dispensing and blending with a conventional carrier, e.g. lactose, present few problems in terms of reproducibility and accuracy. For highly potent drugs, however, accurate blending and dispensing becomes a real problem. When the required drug dose may be as small as 1  $\mu\text{g}$ , contained in an emitted mass of 12-25 mg, the problem of accurate dosing becomes a real impediment to the development of such highly potent drugs.

Summary of the Invention

20 Microparticles according to the present invention, of which at least 90% can have a size of 1-10  $\mu\text{m}$ , are intended for use in gene therapy, and comprise a substantially uniform mixture of an agent for gene therapy and an excipient.

25 Microparticles of this invention may be formulated with a carrier ("carrier" is used herein for distinction from the "excipient" in the microparticles). The formulation may be administered, e.g. from a dry powder inhaler. On administration, the carrier disperses in the 30 airstream; because of its large size, it is deposited in the mouth and throat. The smaller microparticles go to the peripheral airways; on reaching the lung, the excipient dissolves and its diluting effect is lost. The dispersed therapeutic agent is reproducibly dosed to the desired 35 locus of administration.

Description of the Invention

Microparticles of this invention may be obtained by spray-drying under conditions described in WO-A-9609814, the contents of which are incorporated herein by reference.

5 Formulations containing them overcome some of the fundamental problems associated with dry powders for DPIs, specifically, poor powder mixing and limited accuracy of blending and dosing for highly potent drugs.

Particles of the same size are also suitable for  
10 intravenous administration, e.g. for targeted delivery to the liver, and for gene therapy. Soluble microparticles prepared by spray-drying may be cross-linked, by known technology, for this purpose. By comparison with, say, iv administration of adenovirus, targeted administration is  
15 achieved by means of the invention.

More generally, a process for preparing microcapsules of the invention comprises atomising a solution (or dispersion) of excipient and a therapeutic agent that is itself, or is used together with, a wall-forming material.  
20 In particular, it has been found that, under the conditions stated herein, and more generally described in WO-A-9218164, remarkably smooth spherical microparticles of various materials may be produced. The particle size and size distribution of the product can be reproducibly  
25 controlled within a tight range. For example, by Coulter analysis, 98% of the particles can be smaller than 6  $\mu\text{m}$  on a number basis, within an interquartile range of 2  $\mu\text{m}$ , and with less than 0.5  $\mu\text{m}$  mean size variation between batches. Furthermore, when tested in a dry powder inhaler,  
30 reproducible dosing was achieved, and subsequent aerosolisation under normal but low flow conditions (30 l/min) resulted in excellent separation of microparticles from carrier.

The therapeutic agent that is used in this invention  
35 is intended for gene therapy. It may be a naked or encapsulated gene. Alternatively, it may be a virus particle that is stabilised by the presence of the

excipient. Agents suitable for use in gene therapy are receptor-targeted complexes, adenovirus, adeno-associated virus, retrovirus, parvovirus, vaccinia virus, herpes virus and sindbis virus. Cationic lipid-DNA complexes may be 5 used.

Antisense oligonucleotides may also be administered by means of this invention. For example, the oligonucleotide may be chosen to degenerate the template activity of template RNAs. It is demonstrated by Nyce and Metzger, 10 *Nature* 385:721-5 (1997), that aerosolised phosphorothioate antisense oligonucleotide targeting the adenosine A<sub>1</sub> receptor desensitised rabbits to subsequent challenge with adenosine or dust-mite allergen, and is therefore of potential utility in the treatment of asthma.

15 DNA being anionic, microparticles of the invention may comprise a cationic material. In particular, cationic lipids capable of forming positively-charged liposomes have the ability to bind DNA and can be used for gene delivery to mammalian cells both *in vitro* and *in vivo*. By way of 20 example, DNA may be encapsulated by binding to lipid domains in a lactose or other carrier. Ideally, the lipid domains should be <1  $\mu\text{m}$  and the microcapsules of the order of 2-5  $\mu\text{m}$ , for deposition in the peripheral airways. The principle has been tested using control lipids and control 25 DNA and the methodology transferred to produce an active plasmid DNA/lipid/lactose microcapsule using the lipids DC-Chol and DOPE and marker plasmid.

Other suitable cationic materials are chitosan and 30 lysine. Lysine has a very polar side-chain which is positively charged at neutral pH and highly hydrophilic. These properties make it suitable for co-spray-drying with HSA (human serum albumin), to form microcapsules. Successful DNA binding has been achieved on microparticles containing 5% w/w of 25% lysine:75% HSA.

35 Chitosan is a natural polysaccharide suitable for biomedical applications. Lysozyme will biodegrade chitosan *in vivo*. By cross-linking the polymer matrix using heat or

chemical methods, e.g. glycolaldehyde, chitosan becomes less susceptible to lysosomal degradation and thus suitable for prolonged delivery of drugs. The cationic property of the chitosan has proved to bind DNA.

5 The excipient will usually be chosen on account of its ability to dilute/stabilise the therapeutic agent, and because of its wall-forming properties. It should be capable of formulation for spray-drying. Suitable excipients include carbohydrates, e.g. sugars such as 10 glucose, lactose and mannitol.  $\alpha$ -Lactose and mannitol may have the particularly desirable property of resisting moisture uptake. See also EP-A-0372777 (incorporated herein by reference).

15 The amount of excipient in the mixture of the microparticles will usually be chosen having regard to the desired degree of, say, dilution or stabilisation. It may be at least 50% by weight of the mixture, and often at least 70% or 80%.

20 Another inert wall-forming, material may also be used, if desired, to form the microparticles. Suitable such materials are water-soluble.

25 The wall-forming material and process conditions should be so chosen that the product is sufficiently non-toxic and non-immunogenic in the conditions of use, which will clearly depend on the dose administered and duration of treatment. The wall-forming material may be a starch derivative, a synthetic polymer such as tert-butyloxy-carbonylmethyl polyglutamate (US-A-4888398) or a polysaccharide such as polydextrose. Generally, the wall-forming material can be selected from most hydrophilic, 30 biodegradable physiologically compatible polymers, as described in more detail in WO-A-9218164.

35 Especially for pulmonary delivery, the microparticles are preferably soluble, and preferably comprise a carbohydrate excipient. A sugar may facilitate dissolution of the microparticles on the lung surface.

For parenteral administration in particular, the microparticles are preferably stabilised, e.g. cross-linked by chemical means or heat. In this case, a wall-forming material used for gene therapy may be proteinaceous. For 5 example, it may be collagen, gelatin or (serum) albumin, in each case preferably of human origin (i.e. derived from humans or corresponding in structure to the human protein). Most preferably, it is HSA derived from blood donations or, ideally, derived recombinantly from the fermentation of 10 microorganisms (including cell lines) which have been transformed or transfected to express recombinant serum albumin. Further detail is given in WO-A-9218164.

For use in a DPI, microparticles of the invention may be mixed with a conventional carrier such as mannitol, 15 lactose or glucose (which may be the same as the excipient). The carrier will have a particle size, and be in an amount, chosen in accordance with approved usage of the device. By way of example, 3  $\mu\text{m}$  microparticles of the invention may be mixed with lactose particles 80  $\mu\text{m}$  in 20 size.

There are various considerations, in determining an appropriate percentage of the agent to total solids in the spray-drying medium. These criteria include the dose of the agent from one "shot" of the device; the dispensed 25 weight of the formulation, i.e. the amount of powder in one "shot"; and the microparticle:carrier ratio, i.e. the proportion of microcapsules to carrier.

The spray-drying process can be controlled in order to obtain microspheres with desired characteristics. Thus, 30 the pressure at which the seed solution is supplied to the spray nozzle may be varied, for example from  $1.0-10.0 \times 10^5$  Pa, preferably  $2-8 \times 10^5$  Pa, and most preferably about  $7.5 \times 10^5$  Pa. Other parameters may be varied as disclosed below.

35 More than 30%, preferably more than 40%, 50%, or 60%, of the microspheres have a diameter within a 2  $\mu\text{m}$  range and at least 90%, preferably at least 95% or 99%, have a

diameter within the range 1.0-8.0  $\mu\text{m}$ . The interquartile range may be 2  $\mu\text{m}$ , with a median diameter of 3.5, 4.0, 4.5, 5.0, 5.5, 6.0 or 6.5  $\mu\text{m}$ .

Thus, at least 30%, 40%, 50% or 60% of the 5 microspheres may have diameters within the range 1.5-3.5  $\mu\text{m}$ , 2.0-4.0  $\mu\text{m}$ , 3.0-5.0  $\mu\text{m}$ , 4.0-6.0  $\mu\text{m}$ , 5.0-7.0  $\mu\text{m}$  or 6.0-8.0  $\mu\text{m}$ . Preferably, a said percentage of the microspheres have diameters within a 1.0  $\mu\text{m}$  range, such as 1.5-2.5  $\mu\text{m}$ , 2.0-3.0  $\mu\text{m}$ , 3.0-4.0  $\mu\text{m}$ , 4.0-5.0  $\mu\text{m}$ , 5.0-6.0  $\mu\text{m}$ , 6.0-7.0  $\mu\text{m}$  10 or 7.0-8.0  $\mu\text{m}$ .

A product of the invention may be in the form of hollow microspheres, in which at least 90%, preferably at least 95% or 99%, of the microspheres have a diameter in the range 1.0-8.0  $\mu\text{m}$ .

15 For spray-drying, a solution, suspension, emulsion or dispersion preferably contains 0.1 to 50% w/v, more preferably about 5.0-25.0%, of the materials of microcapsules. About 20% is optimal.

20 The solution or dispersion (preferably solution), referred to herein as the "seed solution", is atomised and spray-dried by any suitable technique which results in discrete microspheres or microcapsules of 1 to 10  $\mu\text{m}$  diameter. These figures refer to at least 90% of the population of microcapsules, the diameter being measured 25 with a Coulter Multisizer II. The term "microcapsules" means hollow particles enclosing a space, which space is filled with a gas or vapour but not with any solid materials.

30 The atomising comprises forming an aerosol of the preparation by, for example, forcing the preparation through at least one orifice under pressure into, or by using a centrifugal atomiser in a chamber of warm air or other inert gas. The chamber should be big enough for the largest ejected drops not to strike the walls before 35 drying. The gas or vapour in the chamber is clean (i.e. preferably sterile and pyrogen-free) and non-toxic when administered into the bloodstream in the amounts

concomitant with administration of the microcapsules in use. The rate of evaporation of the liquid from the preparation should be sufficiently high to form hollow microcapsules but not so high as to burst the 5 microcapsules. The rate of evaporation may be controlled by varying the gas flow rate, concentration of drug and excipient in the seed solution, nature of liquid carrier, feed rate of the solution and, more importantly, the temperature of the gas encountered by the aerosol. With an 10 albumin concentration of 15-25% in water, an inlet gas temperature of at least about 100°C, preferably at least 110°C, is generally sufficient to ensure hollowness and the temperature may be as high as 250°C without the capsules bursting. About 180-240°C, preferably about 210-230°C and 15 most preferably about 220°C, is optimal, at least for albumin. Since the temperature of the gas encountered by the aerosol will depend also on the rate at which the aerosol is delivered and on the liquid content of the protein preparation, the outlet temperature may be 20 monitored to ensure an adequate temperature in the chamber. An outlet temperature of 40-150°C has been found to be suitable. Controlling the flow rate has been found to be useful in controlling the other parameters such as the number of intact hollow particles.

25 Due to the heat-sensitive nature of DNA, it would be advantageous to spray-dry using a low outlet temperature. An increase in size has been observed, on reducing the temperature. This size increase may be due to the microcapsules having a higher moisture content which in 30 turn results in particle agglomeration. To avoid this agglomeration, an outlet temperature of 70°C is favoured.

35 More particularly, microparticles of the invention preferably have a maximum interquartile range of 3  $\mu\text{m}$ , more preferably 2  $\mu\text{m}$ , and most preferably 1.5  $\mu\text{m}$ , with respect to their volume median particle size. The volume median particle diameter is determined by Coulter counter. This is achieved by spray-drying in which there is a combination

of low feed stock flow rate with high levels of atomisation and drying air. The effect is to produce microcapsules of very defined size and tight size distribution.

Several workers have designed equations to define the 5 mean droplet size of pneumatic nozzles; a simple version of the various parameters which affect mean droplet size is as follows:

$$D = A / (V^2 \cdot d)^a + B \cdot (M_{air}/M_{liq})^{-b}$$

10

Where      D = Mean droplet size  
A = Constant related to nozzle design  
B = Constant related to liquid viscosity  
V = Relative air velocity between liquid and  
15            nozzle  
d = Air density  
 $M_{air}$  and  $M_{liq}$  = Mass of air and liquid flow  
a and b = Constants related to nozzle design

20            Clearly, for any given nozzle design, the droplet size is most affected by the relative velocity at the nozzle and concurrently the mass ratio of air to liquid. For most common drying use, the air to liquid ratio is in the range of 0.1-10 and at these ratios it appears that the average 25 droplet size is 15-20  $\mu\text{m}$ . For the production of microparticles in the size range described herein, the air to liquid ratio is preferably from 20-1000:1. The effect is to produce particles at the high ratios which are exceedingly small by comparative standards, with very 30 narrow size distributions. For microparticles, produced at the lower ratios of air to liquid, slightly larger particles are produced, but they still nevertheless have tight size distributions which are superior to microparticles produced by emulsion techniques.

35            The invention allows for the nature of the dry microcapsules to be manipulated, in order to optimise the flow or vehicle properties, by changing and reducing the

forces of cohesion and adhesion within the microcapsule preparation. For example, if so required, the microcapsules may be made predominantly positive or negative by the use of highly-charged monomeric or 5 polymeric materials, e.g. lysine or poly-lysine and glutamate or poly-glutamate in systems without HSA or heterogeneous systems including HSA and active principles.

In the Examples, dry powder formulations of gene vectors suitable for pulmonary delivery using a dry powder 10 inhaler device were prepared by spray-drying. The resulting microparticles comprised the gene vector (cationic lipids:DNA complexes or adenovirus) dispersed within the sugar excipient shell. The sugar excipient component of the microparticles enables their dissolution 15 on the lung surface, thereby releasing the gene vector at the optimal site within the lung.

The gene vectors carried reporter genes encoding luciferase or  $\beta$ -galactosidase to investigate DNA activity through the spray drying process. Gene transfection assays 20 were performed on the dry powder formulations of both types of vectors, using *in vitro* cell culture methods.

Example 1

Plasmid pCMVLuc (CMV promoter:luciferase gene) was reconstituted with the lipids DC-Chol/DOPE at a charge 25 ratio of 5:1. DC-Chol is  $3\beta$ -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol; DOPE is dioleoylphosphatidylethanolamine.

A feedstock for spray-drying was prepared containing 1 mg plasmid DNA, 8 mg DC-Chol, 8 mg DOPE and 700 mg 30 lactose as excipient, in 7 ml water. The feed solution was spray-dried using a laboratory bench top spray-dryer, under the following conditions:

	Inlet temperature	130°C
	Outlet temperature	70.1°C
35	Atomisation pressure	3.0 bar
	Feed rate	0.75 g/min

200 mg of spray-dried product was obtained, equivalent to a recovery of 35%. Analysis of the finished product using a Coulter LS230 Laser Sizer demonstrated that the lactose:cationic lipid:DNA microparticles had a median 5 particle diameter (volume) of 3.8  $\mu\text{m}$ . Typically, the cationic lipid:DNA domains were less than 200 nm in size.

Restriction analysis of plasmid DNA extracted from the microparticles using standard procedures demonstrated that the restriction pattern of the spray-dried DNA was 10 identical to that of the control plasmid.

Two such samples (1A and 1B) were prepared. Microcapsules were also prepared comprising lactose only (1C) and lactose:cationic lipid (1D).

A549 cells (derived from a human lung tumour) were 15 grown in 60 mm diameter cell culture dishes. Cells were seeded at  $5 \times 10^5$  the day before transfection. To mimic delivery to the lung, i.e. the use of intra-tracheal powder aerosolisation, the microparticles/microcapsules were sprayed as a dry powder onto the surface of the cells using 20 a syringe device after aspiration of the tissue culture medium. It was estimated that less than 10  $\mu\text{g}$  pCMVLuc DNA was added to each dish. After 30 min, 2 ml fresh cell culture medium was added. At 48 hr post-transfection, 25 cells were lysed in 500  $\mu\text{l}$  lysis buffer (Promega), and the luciferase activity was measured in 20  $\mu\text{l}$  aliquots of cell lysate.

The positive controls were DC-Chol/DOPE (40  $\mu\text{g}$ ):pCMVLuc (10  $\mu\text{g}$ ) in Experiment 1 and Spermidine-Chol/DOPE (40  $\mu\text{g}$ ):pCMVLuc (10  $\mu\text{g}$ ) in Experiment 2. Gene 30 transfection data, expressed in terms of luciferase activity (RLU/min), are given in Table 1. Two values are given, where luciferase activity was measured in two independent dishes.

Table 1

SAMPLE	EXPERIMENT 1 (RLU/min)	EXPERIMENT 2 (RLU/min)
Control Cells	826 776	792
Lactose	830 736	
pCMVLuc	760 810	
+ve Control	8636412 9896528	4192473 3490039
1A	125984 180776	32084 241805
1B	2051592	7505 31604
1C	1392 1394	
1D	878	771

Example 2

15 A plasmid carrying the  $\beta$ -galactosidase gene (CMV promoter) as reporter was reconstituted with the lipid DOTAP, i.e. N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium methylsulphate, and spray-dried with mannitol as excipient. The feedstock contained 2 mg plasmid DNA, 10 mg DOPE and 388 mg mannitol, in 4 ml diluent. The feed solution was spray-dried using a bench 20 top spray dryer under the following conditions:

Inlet temperature                    130°C  
 Outlet temperature                    78°C  
 Atomisation pressure                3.0 bar  
 Feed rate                            0.72 g/min

25 175 mg of spray-dried product was obtained, equivalent to a recovery of 43.8%. Analyses of the spray-dried product on a Coulter LS230 Laser Sizer demonstrated that the microparticles had a median diameter (volume) of 3-6  $\mu$ m.

30 Standard procedures were used to assess gene transfection efficiency. B16 mouse melanoma cells were

seeded at  $10^5$  cells per well and incubated for 24 hr. Samples of cationic lipid:plasmid DNA:mannitol microparticles containing 2  $\mu$ g plasmid DNA were dissolved in water and used to transfect the confluent cells. The 5 controls were 2  $\mu$ g plasmid DNA only and DOTAP/DNA at 2  $\mu$ g DNA. The cells were incubated in the transfection solution for 4 hr and then grown for a further 48 hr before harvesting. Protein extracts were prepared and these were analysed for  $\beta$ -galactosidase activity. Transfection 10 efficiencies in terms of  $\beta$ -galactosidase activity are given in Table 2.

Table 2

Sample	$\beta$ -galactosidase activity (mU/mg protein)	Mean	Standard Deviation
15 Plasmid DNA only	3.41 2.32 2.08	2.60	0.71
DOTAP/DNA	10000.18 9803.90 10142.92	9982.33	170.21
20 DOTAP/DNA/ mannitol microparticles	6530.99 5043.20 5063.85	5546.01	853.08

Example 3

A feedstock was prepared containing an adenoviral vector (luciferase gene as reporter molecule) at a titre of 25  $5.3 \times 10^{10}$  IU/ml ( $7.8 \times 10^{10}$  PFU/ml) in 10 mM Tris, 1 mM MgCl<sub>2</sub>, 150 mM, Tween 80 (54 mg/ml) and 1M sucrose, at pH 8.5. The feedstock (50 ml), at a concentration of 0.352 g/ml, was spray-dried using a laboratory bench top spray-dryer under the following conditions:

30 Inlet temperature	56°C
Outlet temperature	39.9°C
Atomisation pressure	3.0 bar
Feed rate	0.75 g/min

The recovery of product after spray drying is summarised in Table 3.

Table 3

	Before Spray-Drying	Post-Spray-Drying	Recovery
Mass (g)	17.62	6.46	36.6%
Titre (IU/ml)	$5.3 \times 10^{10}$	$2.6 \times 10^{10}$	49.0%

10 The dry powder microparticle formulation of adenovirus was investigated for gene transfection activity in an *in vitro* cell culture assay using A549 cells. The microparticles were dissolved in water, and samples equivalent to 0.5 mg, 2 mg, 5 mg and 20 mg dry powder were 15 used to transfect the cells. Adenovirus at a MOI (multiplicity of infection) of 100 PFU/cell was used as control. All samples were assayed in duplicate. The efficiency of gene transfection measured in luciferase activity is given in Table 4.

20

Table 4

Sample	Luciferase Activity (RLU/min)	
Adenovirus control	17473732	17949356
Adenovirus control	26138380	27845016
+20 mg dry powder	42104272	42878048
+2 mg dry powder	13697072	13401940
+0.5 mg dry powder	5214460	5816246
+5 mg dry powder	24963076	24989568
Control	760	574
Control	203	183

These data demonstrate that the adenovirus retains significant gene transfection activity.

CLAIMS:

1. Microparticles, which are smooth and spherical, at least 90% of which have a particle size of 1 to 10  $\mu\text{m}$ , and which comprise a substantially uniform mixture of an agent for gene therapy and an excipient.  
5
2. Microparticles according to claim 1, wherein the excipient constitutes a major proportion of the mixture.
3. Microparticles according to claim 1 or claim 2, obtainable by spray-drying a solution of the mixture.
- 10 4. Microparticles according to any preceding claim, wherein said particle size is 1 to 5  $\mu\text{m}$ .
5. Microparticles according to any preceding claim, which have a maximum interquartile range of 3  $\mu\text{m}$ .
- 15 6. Microparticles according to claim 5, which have a maximum interquartile range of 2  $\mu\text{m}$ .
7. Microparticles according to any preceding claim, obtainable by an aseptic process.
8. Microparticles according to any preceding claim, wherein the excipient comprises a carbohydrate.
- 20 9. Microparticles according to any preceding claim, wherein said agent is a naked or encapsulated gene, or a virus particle.
10. Microparticles according to any preceding claim, which additionally comprises a cationic material, and wherein  
25 said agent comprises DNA.
11. Microparticles according to claim 10, wherein the cationic material comprises lipid domains.
12. A free-flowing particulate composition comprising microparticles according to any preceding claim and  
30 relatively large particles of a carrier material which may be the same as or different from the excipient.
13. An inhaler device adapted to deliver a therapeutic agent via the pulmonary airways, which comprises a composition according to claim 12.
- 35 14. Use of an agent for gene therapy, for the manufacture of a medicament for treatment of a complaint on which the said agent acts on administration via the pulmonary

airways, characterised in that the medicament is in the form of microparticles according to any of claims 1 to 11 or a composition according to claim 12.

15. In a method of treating a complaint by administration 5 to the patient of an effective amount of an agent for gene therapy that acts via pulmonary airways to treat the complaint, the improvement comprising administration of said agent in the form of microparticles according to claim 1.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 97/00953

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 9/16, A61K 9/48, A61K 9/50, A61K 9/72, A61K 48/00  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 9703702 A1 (BROWN UNIVERSITY RESEARCH FOUNDATION), 6 February 1997 (06.02.97) --	1-14
P,X	WO 9627393 A1 (UNIVERSITY OF PITTSBURGH), 12 Sept 1996 (12.09.96) --	1-14
P,X	WO 9609814 A1 (ANDARIS LIMITED), 4 April 1996 (04.04.96) --	1-14
X	EP 0611567 A1 (TEIJIN LIMITED), 24 August 1994 (24.08.94) --	1-14

Further documents are listed in the continuation of Box C.

See patent family annex.

- \* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

22 July 1997

Date of mailing of the international search report

14.08.97

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentdaan 2  
NL-2280 HV Rijswijk  
Tel. (- 31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (- 31-70) 340-3016

Authorized officer

## INTERNATIONAL SEARCH REPORT

International application No. PCT/GB 97/00953
--------------------------------------------------

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0606486 A1 (TEIJIN LIMITED), 20 July 1994 (20.07.94) --	1-14
A	WO 9423699 A1 (MEDISORB TECHNOLOGIES INTERNATIONAL L.P.), 27 October 1994 (27.10.94) --	1-12
A	WO 9218164 A1 (DELTA BIOTECHNOLOGY LIMITED), 29 October 1992 (29.10.92) --	1-14
A	WO 9531479 A1 (INHALE THERAPEUTIC SYSTEMS, INC.), 23 November 1995 (23.11.95) --	1-14
A	Eur. J. Pharm. Biopharm., Volume 40, No 4, 1994, Ubaldo Conte et al, "Spray Dried Albumin Microspheres Containing Nicardipine" page 203 - page 208 -- -----	1-14

## INTERNATIONAL SEARCH REPORT

I national application No.

PCT/GB 97/00953

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 15  
because they relate to subject matter not required to be searched by this Authority, namely:  
See PCT Rule 39.1(iv): Methods for treatment of the human/animal body  
by surgery or therapy, as well as diagnostic methods.
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

SA '56833

Information on patent family members

01/07/97

International application No.  
PCT/GB 97/00953

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9703702 A1	06/02/97	AU 6505096 A		18/02/97
		AU 6762396 A		18/02/97
		WO 9703657 A		06/02/97
WO 9627393 A1	12/09/96	AU 5417796 A		23/09/96
WO 9609814 A1	04/04/96	AU 3530295 A		19/04/96
		CA 2199954 A		04/04/96
		NO 971438 A		26/03/97
EP 0611567 A1	24/08/94	AU 659328 B		11/05/95
		AU 4355693 A		04/01/94
		JP 62249892 A		30/10/87
		AU 660824 B		06/07/95
		AU 4355593 A		04/01/94
		CA 2115065 A		23/12/93
		CA 2115444 A		23/12/93
		EP 0606486 A		20/07/94
		US 5626871 A		06/05/97
		WO 9325193 A		23/12/93
		WO 9325198 A		23/12/93
EP 0606486 A1	20/07/94	AU 660824 B		06/07/95
		AU 4355593 A		04/01/94
		JP 1716113 C		27/11/92
		JP 4001553 B		13/01/92
		JP 61252769 A		10/11/86
		US 5626871 A		06/05/97
		AU 659328 B		11/05/95
		AU 4355693 A		04/01/94
		CA 2115065 A		23/12/93
		CA 2115444 A		23/12/93
		EP 0611567 A		24/08/94
		WO 9325193 A		23/12/93
		WO 9325198 A		23/12/93
WO 9423699 A1	27/10/94	AU 6637394 A		08/11/94
		CA 2160877 A		27/10/94
		EP 0695170 A		07/02/96
		JP 8511418 T		03/12/96
WO 9218164 A1	29/10/92	AU 655016 B		01/12/94
		AU 1589192 A		17/11/92
		AU 7448394 A		22/12/94
		CN 1066977 A		16/12/92
		EP 0512693 A		11/11/92
		EP 0533886 A		31/03/93
		EP 0681843 A		15/11/95
		GB 2260745 A,B		28/04/93
		HU 9203891 D		00/00/00
		NZ 242328 A		22/12/94
		US 5518709 A		21/05/96

**INTERNATIONAL SEARCH REPORT**

SA '56833

Information on patent family members

01/07/97

International application No.  
PCT/GB 97/00953

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9531479 A1	23/11/95	AU 2514295 A CA 2190502 A EP 0759939 A	05/12/95 23/11/95 05/03/97